Ocrelizumab in multiple sclerosis: risks and benefits

Lancet. 2012 Mar 31;379(9822):1196-7; author reply 1197. doi: 10.1016/S0140-6736(12)60508-X.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Female
  • Humans
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*

Substances

  • Antibodies, Monoclonal, Humanized